Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
Medical News Today2d
New test may predict which IBD patients have higher colorectal cancer risk
Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...
The Lancet2d
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...
Knowridge4h
Gut worms may help treat inflammatory bowel disease
Scientists have discovered that tiny particles released by a type of intestinal worm might help reduce inflammation in people with inflammatory bowel disease (IBD). This condition affects millions of ...
Armed robbery in Revesby2d
Breakthrough IBD Treatment Heads Into Clinical Trials
People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Ulcerative Colitis Market: A Comprehensive Overview And Future Outlook
PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...
Daily7h
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis
Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...
2minutemedicine.com2d
Fecal Microbiota, live-jslm may be an effective means of preventing Clostridiodes difficile infections in patients with inflammatory bowel disease
The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection ...
Pharmabiz9h
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis
Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...